EUCTR2007-001361-15-DE进行中（未招募）不适用
An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients of any race, 18 years or older
- •2. Primary orthotopic liver transplant recipients.
- •3. Allograft is functioning at an acceptable level by 24 hrs as determined by local
- •investigator
- •4. Recipients have been initiated on tacrolimus therapy with or without MPA (within 12 hours of transplantation).
- •5. Females capable of becoming pregnant must have a negative pregnancy test within 7 days
- •prior to enrollment.
- •6. Able to communicate well with the investigator, to understand and comply with the
- •requirements of the study. Understand and sign the written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Recipients of prior organ transplants or patients recipients of multiple organ transplants
- •(including combined liver- kidney transplantation).
- •2. Recipients of ABO incompatible transplants.
- •3. Recipients of living donor or split-liver transplants
- •4. Transplant with a cold ischemic time of >12 hours.
- •5. Transplants of donors after cardiac death (DCD).
- •6. Patients with a MELD-score >35 during 1 month prior transplantation
- •7. Transplant of a marginal graft into a patient with a MELD-score > 28 defined by any of the following criteria: donor age > 60, CIT > 10h, hypotension periods or inotropic support of the donor, stay on ICU > 3 days, graft steatosis > 30%
- •8. Patients with acute, fulminant hepatic failure (UNOS I, T1)
- •9. Patients who are anti-HIV-positive
- •10. Patients with any past or present malignancy (other than excised basal cell carcinoma and
- •hepato-cellular carcinoma (HCC).
- •11. Patients with a serum creatinine > 4.0 mg/dL or on dialysis
- •12. Patients who received any investigational drug within 4 weeks prior to baseline or who are currently enrolled in a clinical trial.
- •13. Patients who have received or are expected to receive induction antibody or any other immunosuppressive therapy not defined in the protocol.
- •14. Patients who display hypersensitivity or contraindication to study drugs AEB071, MPA, tacrolimus or corticosteroids.
- •15. Patients who are requiring the administration of strongly interacting drugs of the CYP450 3A4/5 system ( See Appendix 5).
- •16. Patients with active or history of clinically significant cardiac abnormalities, for example
- •Patients requiring drugs with QT-prolonging properties (e.g. antiarrhythmic drugs, such as amiodarone, sotalol, dofetilide, quinidine, procainamide, disopyramide)
- •Patients with QTcF >470msec (Friderica´s correction), long QT-syndrome (own or with a family history) or with a family history of sudden unexplained death.
- •Patients with left branch bundle block (LBBB), or who have been hospitalized for heart failure of cardiac etiology in the previous 6 months, have significant and persistent left-ventricular dysfunction (LVEF < 40%), etc.
- •Patients with a history, in the preceding 3 months, of significant and persistent arrhythmias such as ventricular fibrillation or tachycardia, or atrial fibrillation or flutter.
- •Patients with symptomatic coronary artery disease
- •Presence of severe cardiac disease (= Old New York Heart Association Classification Grade III), elevated CPK, and/or abnormal ECG, considered by the investigator to be unsafe for the study.
- •17. Patients with an absolute neutrophil count of < 1,500/mm3, or absolute leukocytes count <2,500/mm3, or platelets < 40’000/mm3.
- •18. Patients with severe active infection considered by the investigator to be unsafe for the study.
- •19. Existence of any surgical or medical condition, other than the current transplant, which, in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism, or excretion of the study medication.
- •20. Abnormal physical or laboratory findings or mental disorders of clinical significance within 2 weeks prior to randomization that, in the opinion of the investigator, might interfere with the objectives of the study.
研究者
相似试验
进行中（未招募）
不适用
An open-label, two-period, multi-center, single dose study to assess the pharmacokinetics of AEB071 in de novo liver transplant patients - NDliver transplantMedDRA version: 6.1Level: PTClassification code 10024714EUCTR2007-001361-15-ITOVARTIS FARMA12
进行中（未招募）
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.EUCTR2014-004693-42-GBIntercept Pharmaceuticals, Inc.72
进行中（未招募）
1 期
A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subjects with Severe SepsisSevere SepsisEUCTR2010-020204-30-GBEisai Limited45
已完成
1 期
A study to find out the variation in the absorption of SPA100 (aliskiren/amlodipine 300/10 mg oral tablets) when given with and with out foodCTRI/2009/091/000762ovartis Healthcare Private Limited,Andhra Pradesh, India 500 081.36
招募中
1 期
ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862EUCTR2022-001837-35-LTBasilea Pharmaceutica International Ltd, Allschwil15